Tolerance and exhaustion: Defining mechanisms of T cell dysfunction

Trends in Immunology

Volumn 35, Issue 2, 2014, Pages 51-60

  Schietinger, Andrea ^a,b   Greenberg, Philip D ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b USA   (United States)

Author keywords

CD8 T cells; Chronic infection; Exhaustion; Self tolerance; T cell differentiation; T cell dysfunction; Tumors

Indexed keywords

IPILIMUMAB;

CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL FATE; CLONAL ANERGY; EPIGENETICS; EXHAUSTION; HUMAN; IMMUNE DEFICIENCY; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE FUNCTION; MEMORY T LYMPHOCYTE; MOLECULAR IMPRINTING; NONHUMAN; PLASTICITY; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; VIRUS INFECTION;

CD8 T CELLS; CHRONIC INFECTION; EXHAUSTION; SELF-TOLERANCE; T CELL DIFFERENTIATION; T CELL DYSFUNCTION; TUMORS;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CLONAL ANERGY; EPIGENESIS, GENETIC; HUMANS; IMMUNE TOLERANCE; IMMUNOLOGIC MEMORY; INFECTION; LYMPHOCYTE ACTIVATION; MICE; NEOPLASMS; SELF TOLERANCE;

EID: 84893711428     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2013.10.001     Document Type: Review

References (121)

1. Kaech S.M., et al. Molecular and functional profiling of memory CD8 T cell differentiation. Cell 2002, 111:837-851.
2. Kaech S.M., Cui W. Transcriptional control of effector and memory CD8+ T cell differentiation. Nat. Rev. Immunol. 2012, 12:749-761.
3. Blackburn S.D., et al. Coregulation of CD8+ T cell exhaustion by multiple inhibitory receptors during chronic viral infection. Nat. Immunol. 2009, 10:29-37.
4. Odorizzi P.M., Wherry E.J. Inhibitory receptors on lymphocytes: insights from infections. J. Immunol. 2012, 188:2957-2965.
5. Baitsch L., et al. The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012, 33:364-372.
6. Kim P.S., Ahmed R. Features of responding T cells in cancer and chronic infection. Curr. Opin. Immunol. 2010, 22:223-230.
7. Wherry E.J. T cell exhaustion. Nat. Immunol. 2011, 12:492-499.
8. Grosso J.F., et al. LAG-3 regulates CD8+ T cell accumulation and effector function in murine self- and tumor-tolerance systems. J. Clin. Invest. 2007, 117:3383-3392.
9. Schietinger A., et al. Rescued tolerant CD8 T cells are preprogrammed to reestablish the tolerant state. Science 2012, 335:723-727.
10. Hogquist K.A., et al. Central tolerance: learning self-control in the thymus. Nat. Rev. Immunol. 2005, 5:772-782.
11. Hernandez J., et al. Phenotypic and functional analysis of CD8(+) T cells undergoing peripheral deletion in response to cross-presentation of self-antigen. J. Exp. Med. 2001, 194:707-717.
12. Redmond W.L., et al. Distinct requirements for deletion versus anergy during CD8 T cell peripheral tolerance in vivo. J. Immunol. 2005, 174:2046-2053.
13. Kurts C., et al. Class I-restricted cross-presentation of exogenous self-antigens leads to deletion of autoreactive CD8(+) T cells. J. Exp. Med. 1997, 186:239-245.
14. Wing K., Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat. Immunol. 2010, 11:7-13.
15. Redmond W.L., Sherman L.A. Peripheral tolerance of CD8 T lymphocytes. Immunity 2005, 22:275-284.
16. Mueller D.L. Mechanisms maintaining peripheral tolerance. Nat. Immunol. 2010, 11:21-27.
17. Steinman R.M., et al. Tolerogenic dendritic cells. Annu. Rev. Immunol. 2003, 21:685-711.
18. Heath W.R., Carbone F.R. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 2001, 19:47-64.
19. Ohlen C., et al. CD8(+) T cell tolerance to a tumor-associated antigen is maintained at the level of expansion rather than effector function. J. Exp. Med. 2002, 195:1407-1418.
20. Rocha B., et al. Clonal anergy blocks in vivo growth of mature T cells and can be reversed in the absence of antigen. J. Exp. Med. 1993, 177:1517-1521.
21. Ramsdell F., Fowlkes B.J. Maintenance of in vivo tolerance by persistence of antigen. Science 1992, 257:1130-1134.
22. Calbo S., et al. Functional tolerance of CD8+ T cells induced by muscle-specific antigen expression. J. Immunol. 2008, 181:408-417.
23. Pittet M.J., et al. High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals. J. Exp. Med. 1999, 190:705-715.
24. Ohashi P.S., et al. Ablation of "tolerance" and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 1991, 65:305-317.
25. Overwijk W.W., et al. Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. J. Exp. Med. 2003, 198:569-580.
26. Parish I.A., Heath W.R. Too dangerous to ignore: self-tolerance and the control of ignorant autoreactive T cells. Immunol. Cell Biol. 2008, 86:146-152.
27. Kurts C., et al. CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc. Natl. Acad. Sci. U.S.A. 1999, 96:12703-12707.
28. Oldstone M.B., et al. Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: role of anti-self (virus) immune response. Cell 1991, 65:319-331.
29. Lang K.S., et al. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat. Med. 2005, 11:138-145.
30. Millar D.G., et al. Hsp70 promotes antigen-presenting cell function and converts T-cell tolerance to autoimmunity in vivo. Nat. Med. 2003, 9:1469-1476.
31. Ramanathan S., et al. Exposure to IL-15 and IL-21 enables autoreactive CD8 T cells to respond to weak antigens and cause disease in a mouse model of autoimmune diabetes. J. Immunol. 2011, 186:5131-5141.
32. Schier W.W. Cutaneous anergy and Hodgkin's disease. N. Engl. J. Med. 1954, 250:353-361.
33. Ashikawa K., et al. Immune response in tumor-bearing patients and animals. II. Incidence of tuberculin anergy in cancer patients. Gann 1967, 58:565-573.
34. Schwartz R.H. T cell anergy. Annu. Rev. Immunol. 2003, 21:305-334.
35. Choi S., Schwartz R.H. Molecular mechanisms for adaptive tolerance and other T cell anergy models. Semin. Immunol. 2007, 19:140-152.
36. Jenkins M.K., Schwartz R.H. Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J. Exp. Med. 1987, 165:302-319.
37. Zheng Y., et al. Transcriptional regulator early growth response gene 2 (Egr2) is required for T cell anergy in vitro and in vivo. J. Exp. Med. 2012, 209:2157-2163.
38. Villarino A.V., et al. Posttranscriptional silencing of effector cytokine mRNA underlies the anergic phenotype of self-reactive T cells. Immunity 2011, 34:50-60.
39. Macian F., et al. Transcriptional mechanisms underlying lymphocyte tolerance. Cell 2002, 109:719-731.
40. Teague R.M., et al. Interleukin-15 rescues tolerant CD8+ T cells for use in adoptive immunotherapy of established tumors. Nat. Med. 2006, 12:335-341.
41. Teague R.M., et al. Peripheral CD8+ T cell tolerance to self-proteins is regulated proximally at the T cell receptor. Immunity 2008, 28:662-674.
42. Oelert T., et al. Irradiation and IL-15 promote loss of CD8 T-cell tolerance in response to lymphopenia. Blood 2010, 115:2196-2202.
43. Gattinoni L., et al. Removal of homeostatic cytokine sinks by lymphodepletion enhances the efficacy of adoptively transferred tumor-specific CD8+ T cells. J. Exp. Med. 2005, 202:907-912.
44. Johnson L.D., Jameson S.C. Self-specific CD8+ T cells maintain a semi-naive state following lymphopenia-induced proliferation. J. Immunol. 2010, 184:5604-5611.
45. DeSilva D.R., et al. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J. Immunol. 1991, 147:3261-3267.
46. Brown I.E., et al. Homeostatic proliferation as an isolated variable reverses CD8+ T cell anergy and promotes tumor rejection. J. Immunol. 2006, 177:4521-4529.
47. Krupica T., et al. Autoimmunity during lymphopenia: a two-hit model. Clin. Immunol. 2006, 120:121-128.
48. King C., et al. Homeostatic expansion of T cells during immune insufficiency generates autoimmunity. Cell 2004, 117:265-277.
49. Le Campion A., et al. Lymphopenia-induced spontaneous T-cell proliferation as a cofactor for autoimmune disease development. Blood 2009, 114:1784-1793.
50. Datta S., Sarvetnick N. Lymphocyte proliferation in immune-mediated diseases. Trends Immunol. 2009, 30:430-438.
51. Jones R.J., et al. Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1989, 1:754-757.
52. Goldberg A.D., et al. Epigenetics: a landscape takes shape. Cell 2007, 128:635-638.
53. Guil S., Esteller M. DNA methylomes, histone codes and miRNAs: tying it all together. Int. J. Biochem. Cell Biol. 2009, 41:87-95.
54. Cuddapah S., et al. Epigenomics of T cell activation, differentiation, and memory. Curr. Opin. Immunol. 2010, 22:341-347.
55. Zediak V.P., et al. The contribution of epigenetic memory to immunologic memory. Curr. Opin. Genet. Dev. 2011, 21:154-159.
56. Youngblood B., et al. T-cell memory differentiation: insights from transcriptional signatures and epigenetics. Immunology 2013, 139:277-284.
57. Denton A.E., et al. Differentiation-dependent functional and epigenetic landscapes for cytokine genes in virus-specific CD8+ T cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:15306-15311.
58. Schmidl C., et al. Lineage-specific DNA methylation in T cells correlates with histone methylation and enhancer activity. Genome Res. 2009, 19:1165-1174.
59. Araki Y., et al. Genome-wide analysis of histone methylation reveals chromatin state-based regulation of gene transcription and function of memory CD8+ T cells. Immunity 2009, 30:912-925.
60. Weng N.P., et al. The molecular basis of the memory T cell response: differential gene expression and its epigenetic regulation. Nat. Rev. Immunol. 2012, 12:306-315.
61. Youngblood B., et al. Making memories that last a lifetime: heritable functions of self-renewing memory CD8 T cells. Int. Immunol. 2010, 22:797-803.
62. Rothenberg E.V., Zhang J.A. T-cell identity and epigenetic memory. Curr. Top. Microbiol. Immunol. 2012, 356:117-143.
63. Han S., et al. Role of antigen persistence and dose for CD4+ T-cell exhaustion and recovery. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:20453-20458.
64. Wherry E.J., et al. Antigen-independent memory CD8 T cells do not develop during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:16004-16009.
65. Utzschneider D.T., et al. T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansion. Nat. Immunol. 2013, 14:603-610.
66. Angelosanto J.M., et al. Progressive loss of memory T cell potential and commitment to exhaustion during chronic viral infection. J. Virol. 2012, 86:8161-8170.
67. Moskophidis D., et al. Virus persistence in acutely infected immunocompetent mice by exhaustion of antiviral cytotoxic effector T cells. Nature 1993, 362:758-761.
68. Wherry E.J., et al. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 2003, 77:4911-4927.
69. Wherry E.J., Ahmed R. Memory CD8 T-cell differentiation during viral infection. J. Virol. 2004, 78:5535-5545.
70. Trautmann L., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 2006, 12:1198-1202.
71. Day C.L., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006, 443:350-354.
72. Barber D.L., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 2006, 439:682-687.
73. Petrovas C., et al. PD-1 is a regulator of virus-specific CD8+ T cell survival in HIV infection. J. Exp. Med. 2006, 203:2281-2292.
74. Keir M.E., et al. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 2008, 26:677-704.
75. Nishimura H., et al. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 1999, 11:141-151.
76. Youngblood B., et al. Chronic virus infection enforces demethylation of the locus that encodes PD-1 in antigen-specific CD8(+) T cells. Immunity 2011, 35:400-412.
77. Youngblood B., et al. Cutting edge: prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells. J. Immunol. 2013, 191:540-544.
78. Duraiswamy J., et al. Phenotype, function, and gene expression profiles of programmed death-1(hi) CD8 T cells in healthy human adults. J. Immunol. 2011, 186:4200-4212.
79. Quigley M., et al. Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF. Nat. Med. 2010, 16:1147-1151.
80. Zinselmeyer B.H., et al. PD-1 promotes immune exhaustion by inducing antiviral T cell motility paralysis. J. Exp. Med. 2013, 210:757-774.
81. Norris B.A., et al. Chronic but not acute virus infection induces sustained expansion of myeloid suppressor cell numbers that inhibit viral-specific T cell immunity. Immunity 2013, 38:309-321.
82. Teijaro J.R., et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 2013, 340:207-211.
83. Wilson E.B., et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 2013, 340:202-207.
84. Doering T.A., et al. Network analysis reveals centrally connected genes and pathways involved in CD8+ T cell exhaustion versus memory. Immunity 2012, 37:1130-1144.
85. Wherry E.J., et al. Molecular signature of CD8+ T cell exhaustion during chronic viral infection. Immunity 2007, 27:670-684.
86. Wang C., et al. Loss of the signaling adaptor TRAF1 causes CD8+ T cell dysregulation during human and murine chronic infection. J. Exp. Med. 2012, 209:77-91.
87. Rangachari M., et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat. Med. 2012, 18:1394-1400.
88. Shin H., et al. A role for the transcriptional repressor Blimp-1 in CD8(+) T cell exhaustion during chronic viral infection. Immunity 2009, 31:309-320.
89. Paley M.A., et al. Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection. Science 2012, 338:1220-1225.
90. Larsson M., et al. Molecular signatures of T-cell inhibition in HIV-1 infection. Retrovirology 2013, 10:31.
91. Jin X., et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 1999, 189:991-998.
92. Schmitz J.E., et al. Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 1999, 283:857-860.
93. Pircher H., et al. Viral escape by selection of cytotoxic T cell-resistant virus variants in vivo. Nature 1990, 346:629-633.
94. Frebel H., et al. Programmed death 1 protects from fatal circulatory failure during systemic virus infection of mice. J. Exp. Med. 2012, 209:2485-2499.
95. Velu V., et al. Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 2009, 458:206-210.
96. Blackburn S.D., et al. Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:15016-15021.
97. Jin H.T., et al. Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:14733-14738.
98. West E.E., et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J. Clin. Invest. 2013, 123:2604-2615.
99. Vezys V., et al. 4-1BB signaling synergizes with programmed death ligand 1 blockade to augment CD8 T cell responses during chronic viral infection. J. Immunol. 2011, 187:1634-1642.
100. Hayflick L., Moorhead P.S. The serial cultivation of human diploid cell strains. Exp. Cell Res. 1961, 25:585-621.
101. Zippelius A., et al. Effector function of human tumor-specific CD8 T cells in melanoma lesions: a state of local functional tolerance. Cancer Res. 2004, 64:2865-2873.
102. Fourcade J., et al. CD8(+) T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res. 2012, 72:887-896.
103. Woo S.R., et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012, 72:917-927.
104. Fourcade J., et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients. J. Exp. Med. 2010, 207:2175-2186.
105. Matsuzaki J., et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:7875-7880.
106. Baitsch L., et al. Exhaustion of tumor-specific CD8 T cells in metastases from melanoma patients. J. Clin. Invest. 2011, 121:2350-2360.
107. Willimsky G., Blankenstein T. Sporadic immunogenic tumours avoid destruction by inducing T-cell tolerance. Nature 2005, 437:141-146.
108. Willimsky G., et al. Immunogenicity of premalignant lesions is the primary cause of general cytotoxic T lymphocyte unresponsiveness. J. Exp. Med. 2008, 205:1687-1700.
109. Castello G., et al. HCV-related hepatocellular carcinoma: From chronic inflammation to cancer. Clin. Immunol. 2010, 134:237-250.
110. Willimsky G., et al. Virus-induced hepatocellular carcinomas cause antigen-specific local tolerance. J. Clin. Invest. 2013, 123:1032-1043.
111. Kozako T., et al. PD-1/PD-L1 expression in human T-cell leukemia virus type 1 carriers and adult T-cell leukemia/lymphoma patients. Leukemia 2009, 23:375-382.
112. Hodi F.S., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 2010, 363:711-723.
113. Topalian S.L., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 2012, 366:2443-2454.
114. Brahmer J.R., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 2012, 366:2455-2465.
115. Callahan M.K., Wolchok J.D. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J. Leukoc. Biol. 2013, 94:41-53.
116. Duraiswamy J., et al. Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res. 2013, 73:3591-3603.
117. Sakuishi K., et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J. Exp. Med. 2010, 207:2187-2194.
118. Berrien-Elliott M.M., et al. Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance. Cancer Res. 2013, 73:605-616.
119. Wolchok J.D., et al. Nivolumab plus ipilimumab in advanced melanoma. N. Engl. J. Med. 2013, 369:122-133.
120. Hamid O., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N. Engl. J. Med. 2013, 369:134-144.
121. Yao S., et al. Advances in targeting cell surface signalling molecules for immune modulation. Nat. Rev. Drug Discov. 2013, 12:130-146.